BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

530163

KERALAYUR

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

KERALA AYURVEDA LTD. Share Price Update

As of the latest trading session, KERALA AYURVEDA LTD. share price is currently at ₹ 352, which is up by ₹ 13.14 from its previous closing. Today, the stock has fluctuated between ₹ 343.40 and ₹ 360.00. Over the past year, KERALA AYURVEDA LTD. has achieved a return of 10.76 %. In the last month alone, the return has been 0.57 %. Read More...

KERALA AYURVEDA LTD. fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    423.54

  • P/E Ratio (TTM)

    -158.54

  • Beta

    0.67

  • Book Value / share

    33.82

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    -0.08

info icon alternate text

KERALA AYURVEDA LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 19.35
Operating Expense 19.64
Net Profit -0.08
Net Profit Margin (%) -0.41
Earnings Per Share (EPS) -0.07
EBITDA 0.50
Effective Tax Rate (%) 50.00
Particulars SEP 2024 (Values in Cr)
Revenue 18.60
Operating Expense 19.70
Net Profit -0.54
Net Profit Margin (%) -2.90
Earnings Per Share (EPS) -0.38
EBITDA -0.15
Effective Tax Rate (%) 23.94
Particulars JUN 2024 (Values in Cr)
Revenue 15.40
Operating Expense 17.40
Net Profit -1.29
Net Profit Margin (%) -8.37
Earnings Per Share (EPS) -1.01
EBITDA -1.14
Effective Tax Rate (%) 24.85
Particulars MAR 2024 (Values in Cr)
Revenue 17.05
Operating Expense 17.15
Net Profit -0.72
Net Profit Margin (%) -4.22
Earnings Per Share (EPS) -0.81
EBITDA 1.30
Effective Tax Rate (%) -77.49
Particulars DEC 2023 (Values in Cr)
Revenue 17.28
Operating Expense 17.49
Net Profit -0.27
Net Profit Margin (%) -1.56
Earnings Per Share (EPS) -0.18
EBITDA 0.54
Effective Tax Rate (%) -107.69
Particulars MAR 2024 (Values in Cr)
Revenue 67.85
Operating Expense 67.78
Net Profit -0.27
Net Profit Margin (%) -0.39
Earnings Per Share (EPS) -0.25
EBITDA 5.02
Effective Tax Rate (%) 162.79
Particulars MAR 2023 (Values in Cr)
Revenue 59.12
Operating Expense 59.64
Net Profit 2.89
Net Profit Margin (%) 4.88
Earnings Per Share (EPS) 3.09
EBITDA 7.45
Effective Tax Rate (%) -21.94
Particulars MAR 2022 (Values in Cr)
Revenue 51.72
Operating Expense 50.79
Net Profit 0.89
Net Profit Margin (%) 1.72
Earnings Per Share (EPS) 1.17
EBITDA 7.88
Effective Tax Rate (%) 28.45
Particulars MAR 2021 (Values in Cr)
Revenue 40.10
Operating Expense 46.84
Net Profit -4.95
Net Profit Margin (%) -12.34
Earnings Per Share (EPS) -4.38
EBITDA 0.28
Effective Tax Rate (%) 24.77
Particulars MAR 2020 (Values in Cr)
Revenue 50.08
Operating Expense 49.01
Net Profit 0.88
Net Profit Margin (%) 1.75
Earnings Per Share (EPS) 1.12
EBITDA 3.12
Effective Tax Rate (%) 27.86
Particulars MAR 2024 (Values in Cr)
Book Value / Share 26.73
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 3.71
EBITDA Margin 6.74
Particulars MAR 2023 (Values in Cr)
Book Value / Share 5.28
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 12.18
EBITDA Margin 3.11
Particulars MAR 2022 (Values in Cr)
Book Value / Share 5.79
ROE % 13.28
ROCE % 9.31
Total Debt to Total Equity 15.40
EBITDA Margin 12.30
Particulars MAR 2021 (Values in Cr)
Book Value / Share 3.22
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 12.42
EBITDA Margin 1.53
Particulars MAR 2020 (Values in Cr)
Book Value / Share 7.51
ROE % 17.88
ROCE % 6.60
Total Debt to Total Equity 10.80
EBITDA Margin 9.61
Particulars MAR 2024 (Values in Cr)
Book Value / Share 35.22
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 2.20
EBITDA Margin 7.14
Particulars MAR 2023 (Values in Cr)
Book Value / Share 13.77
ROE % 2.03
ROCE % 4.85
Total Debt to Total Equity 4.84
EBITDA Margin 7.88
Particulars MAR 2022 (Values in Cr)
Book Value / Share 10.68
ROE % 5.44
ROCE % 8.40
Total Debt to Total Equity 5.97
EBITDA Margin 14.39
Particulars MAR 2021 (Values in Cr)
Book Value / Share 9.51
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 5.01
EBITDA Margin 0.88
Particulars MAR 2020 (Values in Cr)
Book Value / Share 13.90
ROE % 3.89
ROCE % 2.94
Total Debt to Total Equity 4.05
EBITDA Margin 6.07
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 22.79
Total Assets 140.70
Total Liabilities 140.70
Total Equity 35.13
Share Outstanding 12032451
Price to Book Ratio 7.42
Return on Assets (%) -1.08
Return on Capital (%) -1.49
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.19
Total Assets 114.71
Total Liabilities 114.71
Total Equity 7.88
Share Outstanding 10555670
Price to Book Ratio 6.06
Return on Assets (%) -0.78
Return on Capital (%) -1.12
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.87
Total Assets 110.31
Total Liabilities 110.31
Total Equity 7.94
Share Outstanding 10555670
Price to Book Ratio 7.32
Return on Assets (%) 2.14
Return on Capital (%) 3.03
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 18.55
Total Assets 114.48
Total Liabilities 114.48
Total Equity 5.20
Share Outstanding 10555670
Price to Book Ratio 5.40
Return on Assets (%) -4.23
Return on Capital (%) -5.91
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 6.36
Total Assets 102.96
Total Liabilities 102.96
Total Equity 9.72
Share Outstanding 10555670
Price to Book Ratio 2.63
Return on Assets (%) 3.78
Return on Capital (%) 5.27
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 16.47
Total Assets 124.05
Total Liabilities 124.05
Total Equity 42.37
Share Outstanding 12032451
Price to Book Ratio 7.42
Return on Assets (%) -0.21
Return on Capital (%) -0.27
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1.72
Total Assets 98.70
Total Liabilities 98.70
Total Equity 14.53
Share Outstanding 10555670
Price to Book Ratio 6.06
Return on Assets (%) 2.92
Return on Capital (%) 3.73
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.13
Total Assets 91.69
Total Liabilities 91.69
Total Equity 11.27
Share Outstanding 10555670
Price to Book Ratio 7.32
Return on Assets (%) 0.97
Return on Capital (%) 1.22
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.07
Total Assets 96.22
Total Liabilities 96.22
Total Equity 10.04
Share Outstanding 10555670
Price to Book Ratio 5.40
Return on Assets (%) -5.14
Return on Capital (%) -6.51
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.90
Total Assets 93.60
Total Liabilities 93.60
Total Equity 14.66
Share Outstanding 10555670
Price to Book Ratio 2.63
Return on Assets (%) 0.93
Return on Capital (%) 1.21
Particulars MAR 2024 (Values in Cr)
Net Income 5.73
Cash from Operations 3.28
Cash from Investing -1.25
Cash from Financing 17.64
Net change in Cash 18.41
Free Cash Flow 4.40
Particulars MAR 2023 (Values in Cr)
Net Income 4.26
Cash from Operations 10.22
Cash from Investing -7.21
Cash from Financing -1.13
Net change in Cash 1.50
Free Cash Flow 16.41
Particulars MAR 2022 (Values in Cr)
Net Income 9.32
Cash from Operations -0.50
Cash from Investing -1.90
Cash from Financing -13.27
Net change in Cash -15.68
Free Cash Flow 2.34
Particulars MAR 2021 (Values in Cr)
Net Income -0.41
Cash from Operations 7.42
Cash from Investing -1.43
Cash from Financing 6.20
Net change in Cash 12.19
Free Cash Flow 8.46
Particulars MAR 2020 (Values in Cr)
Net Income 6.08
Cash from Operations 5.20
Cash from Investing -4.02
Cash from Financing 0.84
Net change in Cash 1.81
Free Cash Flow 8.54
Particulars MAR 2024 (Values in Cr)
Net Income 4.25
Cash from Operations -4.21
Cash from Investing -2.17
Cash from Financing 21.14
Net change in Cash 14.75
Free Cash Flow -3.51
Particulars MAR 2023 (Values in Cr)
Net Income 6.81
Cash from Operations 9.11
Cash from Investing -5.32
Cash from Financing -2.27
Net change in Cash 1.52
Free Cash Flow 10.05
Particulars MAR 2022 (Values in Cr)
Net Income 7.12
Cash from Operations 8.75
Cash from Investing 0.82
Cash from Financing -10.51
Net change in Cash -0.94
Free Cash Flow 11.05
Particulars MAR 2021 (Values in Cr)
Net Income -0.52
Cash from Operations -0.91
Cash from Investing -2.10
Cash from Financing 2.18
Net change in Cash -0.83
Free Cash Flow 0.03
Particulars MAR 2020 (Values in Cr)
Net Income 2.43
Cash from Operations 4.70
Cash from Investing -3.93
Cash from Financing 0.28
Net change in Cash 1.06
Free Cash Flow 7.46
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

KERALA AYURVEDA LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
347.20 2.46 redarrow
red-green-graph indicator
7 Bearish
9 Bullish
  • 5 Days 343.90
  • 26 Days 348.90
  • 10 Days 343.90
  • 50 Days 356.10
  • 12 Days 344.30
  • 100 Days 357.00
  • 20 Days 346.80
  • 200 Days 339.40
341.67 PIVOT

First Support

333.33

First Resistance

347.18

Second Support

327.82

Second Resistance

355.52

Third Support

319.48

Third Resistance

361.03

RSI

49.13

ADX

9.66

MACD

-4.58

Williams % R

-42.00

Commodity Channel Index (CCI)

25.93

Date

2025-04-30

Week

5628.00

Same Day

6182.00

Month

5849.00

1 Year

0.68

3 Year

0.71

Over 1 Month

0.57%

down

Over 1 Year

10.76%

down

Over 3 Months

-18.10%

down

Over 3 Years

68.32%

down

Over 6 Months

29.67%

down

Over 5 Years

48.70%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

KERALA AYURVEDA LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
41.38%
Promoter Holdings
58.57%
FII
0.0%
DII
0.03%
Promoter Shares(Pledge Percentage)
13.36%
Name Shares Category
Katra Holdings Ltd 6493435.0 (53.97%) Shareholding of Promoter and Promoter Group
Porinju Veliyath 623000.0 (5.18%) Public Shareholding
Katra Phytochem (india) Private Limited 555000.0 (4.61%) Shareholding of Promoter and Promoter Group
Sanjiv Dhireshbhai Shah 306624.0 (2.55%) Public Shareholding
Dheeraj Kumar Lohia 231726.0 (1.93%) Public Shareholding
Anil Kumar K 183842.0 (1.53%) Public Shareholding
Sashikanth Balachandar 152030.0 (1.26%) Public Shareholding

News

Left Arrow
Right Arrow

KERALA AYURVEDA LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

KERALA AYURVEDA LTD. Share Price

Kerala Ayurveda Ltd was established on 6th July 1992. The Company is engaged in manufacture of Ayurveda products, Ayurveda Research, Academies, Clinics, Hospitals, Ayurvedic Wellness Resorts and Services , cultivation of herbs and maintaining herbarium of medicinal plants. The Company emerged as a frontline manufacturer of speciality patent ayurvedic medicines - tussnil, liposem and mathrukalpam.

The company came out with a public issue in Feb.'95 to part-finance its 7-cr expansion-cum-diversification programme which involve, expansion of its existing facilities; to develop a fully integrated health care system, cultivate medicinal plants and market ayurvedic medicines. It also envisions setting up a hospital.

A modern facility to manufacture patent medicines, tablets, capsules and syrups, is to be set up at Athani, near Alwaye. The company is in the midst of enhancing the installed capacity at its Athani plant to produce traditional ayurvedic medicines. Moreover, the company proposes to organise and relocate its twelve clinics to cover all the principal districts in Kerala and augment facilities at its clinics in Bombay, Madras, Bangalore and Mangalore. In addition, it is increasing the bed strength of its hospital in Alwaye.

Kerala Ayurvedic has won the approval of the Karnataka Toursim Development Department to open a health resort at Bangalore catering exclusively to the high income segments, tourists and NRIs.

The company has a well-entrenched presence in several states due to its 75 franchisees and 400 stockists.

During the year 1999-2000, the company exported medicines worth Rs. 56.43 lacs to USA, UK, Italy, Malaysia, Holland and Japan. Four new products have been developed during the year and intial reports are quite encouraging. Clinical studies conducted for patent products have established their efficiency and has also been affirmed by ayurvedic doctors for prescription.

In Bangalore a new Ayurvedic Health resort has started its operation in March 2001 and the trial run had a good response.The company is planning to develop new methods for rare medicinal plants using biofertilizers.

Katra Healthcare Pvt Ltd was merged with Kerala Ayurveda Pharmacy Ltd in 2006 by way of amalgamation and through the said Scheme, the assets and liabilities of Katra Healthcare Pvt Ltd were transferred to and vested in the Company with effect from 1st April 2005. As per Scheme, on 24th Feb 06 the Company allotted 40,00,000 equity shares amounting to Rs.4 Crores to shareholders of Katra Healthcare Pvt Ltd (KHPL). In the ratio of 4 shares for each shares held by them in 'KHPL'.

During year 2007, the Company increased its stake in AyurvedaGram Heritage Wellness Centre Pvt. Ltd., Bangalore from its holding of 15.55% to 74 % by acquiring an additional 58.45% from the erstwhile promoters. Consequently, AyurvedaGram Heritage Wellness Centre Pvt. Ltd (AHWCP) was made subsidiary of the Company. Apart from this, it launched new medicines such as Ostoact for Osteo Arthritis, Menovin for Menopausal syndrome, Laxinol H as Laxative, Ajax for Male Infertility, Pilogest for Piles and Winsoria for Psoriasis. It renovated the Treatment Centre and Kuroor Mana Heritage Building in order to provide better standards and additional amenities. It acquired 3 wholly owned subsidiaries in USA, namely AYU Inc., AYU Natural Medicine Clinics PS and Ayurvedic Academy Inc. During May, 2007, the Company set up a wholly owned overseas subsidiary in Germany named as 'KatraSoft Europe Gmbh' in order to tap the healthcare related software business opportunities in Europe.'

The newly incorporated subsidiary CMS Katra Holdings LLC, USA had picked up a 51% equity stake in US based CMS Katra Nursing LLC, with an objective of acquiring the entire business and assets of CMS Inc., a leading healthcare staffing company based in Florida, USA during 2007-08. The Company during 2008 set up wo more subsidiaries to provide focus on healthcare services, namely CMS Katra Holdings LLC and KatraSoft Europe GmbH. With this, the total no of overseas Subsidiaries increased to five of which four in USA and one in Germany.

During 2008-09, the Company opened new franchise wellness centers at Gurgaon, Jaipur, Noida and Dehradun. In June 2009, a new subsidiary named M/s. NUTRAVEDA Pte. Ltd., was incorporated in Singapore for marketing natural and herbal value added products globally and thereby deliver wellness and nutritional benefits to the global markets. Modern dosage forms of classical formulations were introduced, such as Kashaya to Kashayam Tablets, medicated oils to creams etc. New formulations were introduced for treating diabetes viz. Trikantika Thailam, Kathakhadiradi Kashayam etc. The Company acquired land near Cochin International Airport to setup a new wellness resort.

In 2011-12, the Company started a Panchakarma Center and Pharmacy at Banaras Hindu University under the Private Public Partnership model at the S S Hospital , Varanasi. During 2012-13, it started a Wellness Resort by the side of River Periyar at Aluva under the name, 'Kerala Ayurveda River Retreat' to provide authentic ayurveda treatments. It established a new Treatment Centre at Mangalore to improve the presence in Karnataka. A new Kerala Ayurveda Academy and Wellness Center was started at Fremont in California . A state-of-the-art Ayurveda teaching facility and treatment center was set up to propogate Ayurveda in the USA.

Parent organization MNC Associate
NSE symbol [-]
Founded 1992
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Kerala Ayurveda Ltd?

Answer Field

The share price of Kerala Ayurveda Ltd for NSE is ₹ 0.00 and for BSE is ₹ 347.20.

What is the Market Cap of Kerala Ayurveda Ltd?

Answer Field

The market cap of Kerala Ayurveda Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 4,17.80 Cr. as of now.

What is the 52 Week High and Low of Kerala Ayurveda Ltd?

Answer Field

The 52 Week High and Low of Kerala Ayurveda Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 486.90 and ₹ 250.00.

How to Buy Kerala Ayurveda Ltd share?

Answer Field

You can trade in Kerala Ayurveda Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Kerala Ayurveda Ltd?

Answer Field

The 1 year returns on the stock has been 10.76%.

What is the Current Share Price of Kerala Ayurveda Ltd?

Answer Field

Kerala Ayurveda Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 347.20 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Kerala Ayurveda Ltd Share?

Answer Field

The market cap of Kerala Ayurveda Ltd for NSE ₹ 0.0 & for BSE ₹ 4,17.80 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Kerala Ayurveda Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Kerala Ayurveda Ltd share is -158.54.

What is the PB ratio of Kerala Ayurveda Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Kerala Ayurveda Ltd share is 33.82.

How to Buy Kerala Ayurveda Ltd Share?

Answer Field

You can trade in Kerala Ayurveda Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Kerala Ayurveda Ltd Share on Bajaj Broking App?

Answer Field

To buy Kerala Ayurveda Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Kerala Ayurveda Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|